After more than a month of speculation over how the FDA will rule on Novavax’s application for an updated formulation of its ...

Vaccine maker Novavax stock jumped double digits on Thursday after the company reported its quarterly sales had more than ...

Novavax posts encouraging first-quarter results on the back of an additional $603 million in revenues recognized from the ...

Nuvaxovid sales reached $608 million, up from $82 million a year ago. Cost of sales for the first quarter of 2025 was $14 million, compared to $59 million in the same period in 2024.

Novavax (NASDAQ:NVAX) shares climbed ~35% in the premarket on Thursday after the COVID-19 vaccine maker lifted its full-year ...

Novavax, Inc. (Nasdaq: NVAX) has updated the terms of the previously announced collaboration and licensing agreement (CLA) ...

Novavax highlighted that they believe their BLA for Nuvaxovid is approvable based on their conversations with the FDA to date and this additional data would be generated after BLA approval ...

Sanofi Supply Sales Novavax will sell Nuvaxovid commercial supply to Sanofi for the 2025-2026 vaccination season and the reimbursement for this supply will be recorded as product sales.

The company noted that the improved financial terms of the amended agreement for the development, manufacturing and commercialization of Nuvaxovid in Japan include an upfront payment, payment ...

Novavax, Inc. (NVAX) said it has updated the terms of the collaboration and licensing agreement with Takeda. The company noted that the improved financial terms of the amended ...

The improved financial terms of the amended agreement for the development, manufacturing and commercialization of Nuvaxovid® in Japan include an upfront payment, payment related to the 2024/2025 ...

FDA feedback on COVID-19 BLA suggests pathway to approval upon alignment on study parameters for the postmarketing commitment requested by FDA SHIELD- Utah study ...